Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides

Rheumatology

Volumn 41, Issue 6, 2002, Pages 691-696

  Vignola, S ^a   Picco, P ^a   Falcini, F ^b   Sabatini, F ^a   Buoncompagni, A ^a   Gattorno, M ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Juvenile idiopathic arthritis; Synovial fluid; Synovial membranes; TNF ; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P75; STEROID; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; PANNUS; PATHOGENESIS; PRIORITY JOURNAL; SERUM; SYNOVIAL FLUID; TISSUE INJURY;

EID: 0036269877     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/41.6.691     Document Type: Article

References (32)

1. Angiogenic factors
2. Angiogenesis
3. Starving the synovium: Angiogenesis and inflammation in rheumatoid arthritis
4. Angiogenesis in cancer, vascular, rheumatoid and other disease
5. Hypoxia augments cytokine (transforming growth factor-beta (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts
6. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β
7. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin e and interleukin-1: A potential mechanism for inflammatory angiogenesis
8. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis
9. Angiogenesis: A critical process in the pathogenesis of RA-a role for VEGF?
10. Vascular endothelial growth factor in patients with rheumatoid arthritis
11. Serum concentrations of vascular endothelial growth factor in collagen disease
12. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis
13. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis
14. Focally regulated endothelial proliferation and cell death in human synovium
15. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997
16. Correlation between conventional disease activity measures in juvenile chronic arthritis
17. Preliminary definition of improvement in juvenile arthritis
18. Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis
19. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
20. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis
21. The pathophysiology of angiogenesis
22. The regulation of neovascularization by matrix metalloproteinases and their inhibitors
23. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
24. Injury induces in vivo expression of platelet-derived growth factor (PDGF) and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts
25. Complex role of matrix metalloproteinases in angiogenesis
26. Matrix metalloproteinases in angiogenesis. A moving target for therapeutic intervention
27. Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications
28. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis
29. Vascular endothelial growth factor, a potent and selective angiogenic agent
30. An antagonist vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells
31. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
32. Target effector role of vascular endothelium in the inflammatory response: Insight from the clinical trials of anti-TNF alpha antibody in rheumatoid arthritis